Disclosure of total number of voting rights and number of shares in the capital as of February, 29 2020 pursuant to article L-223-8 II of the French “Code de Commerce” and 223-16 of the AMF’s General Regulations
Assistance Publique – Hôpitaux de Paris (AP-HP) and Median Technologies reach a research collaboration agreement involving the iBiopsy® platform. The collaboration agreement initially covers two joint clinical studies on liver cancer, involving coordinating investigators from two AP-HP hospitals -Pitié-Salpêtrière and Paul-Brousse-, and Median’s team. The agreement will enable Median to work with large patient cohorts for the clinical validation of iBiopsy®’s AI technologies.
Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2020 pursuant to article L-223-8 II of the French “Code de Commerce” and 223-16 of the AMF’s General Regulations
Press Release – For immediate release – 5:45pm CET Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, announces the publication date for its 2019…
To download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]